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ABSTRACT
Treosulfan (L-threitol-1,4-bismethanesulfonate) is an alkylating agent with routine clinical application in the
treatment of ovarian cancer. In this murine study we show that this drug also has the ability to deplete primitive
hematopoietic stem cells in a dose-dependent manner as determined by the cobblestone area–forming cell
assay and is similar to its parent compound busulfan. Because busulfan is frequently used as part of the
conditioning regimen before stem cell transplantation, we investigated an alternative nonmyeloablative pro-
tocol in an allogeneic bone marrow transplantation model in which low-dose treosulfan was added to an
immune-suppressive regimen consisting of T cell–depleting antibodies, fludarabine, and thymic irradiation.
Although this treatment protocol produced minimal myelosuppression, the addition of treosulfan proved to be
important for allowing stable multilineage and mixed chimerism in C57BL/6 recipients of major histocom-
patibility complex–mismatched B10.A bone marrow without evidence of graft-versus-host disease. Donor
lymphocyte infusion performed at 10 weeks after bone marrow transplantation had the effect of transforming
the state of mixed chimerism to full donor-type cells, again without evidence of graft-versus-host disease.
Donor-specific immunologic tolerance in the mixed chimeric animals was indicated by the acceptance of
donor-type and rejection of third-party skin grafts. Thus, low-dose treosulfan may be considered as a useful
component of a truly nonmyeloablative conditioning protocol in providing for mixed hematopoietic chimerism
and, consequently, in establishing a platform for adoptive immunotherapy.
© 2004 American Society for Blood and Marrow Transplantation
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iNTRODUCTION
Treosulfan (l-threitol-1,4-bismethanesulfonate)
as developed more than 30 years ago as a water-
oluble analog of busulfan and seemed to have com-
arable antitumor activity in chronic myelogenous
eukemia patients [1]. Treosulfan is currently being
sed in Europe as chemotherapy in the treatment of
dvanced ovarian carcinoma [2-4]. In addition, in vitro
nd in vivo activity against other tumors, including d
36uman lung, breast, and renal cell carcinoma and
elanoma, have been reported [5-8], and, more re-
ently, antileukemic activity was demonstrated in hu-
an acute myelogenous leukemia, chronic myeloge-
ous leukemia, acute lymphoblastic leukemia, and
ultiple myeloma models [9-12].
Treosulfan acts as a prodrug that is nonenzymat-
cally converted into the active compound (2S,3S)-
iepoxybutane. This compound, as well as the mono-
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Treosulfan in Nonmyeloablative Conditioning
Bpoxide intermediate, is able to induce alkylation and
ross-linking of DNA. Like the parent compound
usulfan, treosulfan epoxides alkylate at the N7 posi-
ion of guanine [13]. Another important feature of
reosulfan is that it can be easily administered intra-
enously because of its solubility in aqueous solutions.
he dose-limiting side effect of treosulfan is bone
arrow toxicity, with a maximal tolerated dose of 10
/m2 in humans [14]. Previous clinical studies have
hown that the dose can be safely increased up to 47
/m2 when the treatment is followed by an autologous
one marrow transplantation (BMT) [15]. In a more
ecent clinical trial, treosulfan 3  10 g/m2 combined
ith ﬂudarabine 5  30 mg/m2 (plus antithymocyte
lobulin for unrelated donors) has been used before
llogeneic transplantations; 80% of the patients
chieved complete donor-type chimerism, apparently
ithout severe acute or long-lasting side effects [16].
hese clinical ﬁndings are consistent with the hema-
opoietic stem cell–depleting effects of treosulfan, as
ocumented in mice [17], and, in this respect, are
imilar to ﬁndings with busulfan [18].
Reduced-intensity or nonmyeloablative condi-
ioning therapy before allogeneic stem cell transplan-
ation is being increasingly used as a means of induc-
ng a state of mixed hematopoietic chimerism and as a
relude to adoptive immunotherapy with donor lym-
hocyte infusions (DLI) [19]. The components in the
onditioning regimen vary widely among different
linical centers and include varying combinations of
ow-dose total body irradiation [20], busulfan [21-23],
udarabine [24-26], cyclophosphamide [25-27], local-
zed thymic irradiation [27], and additional immune
uppression with various T cell–depleting antibodies
23,26-30]. However, the optimal combinations and
osing for attaining stable engraftment of histoincom-
atible stem cells with minimal complications have yet
o be deﬁned. Although treosulfan is being used at
scalated doses as part of the conditioning regimen in
linical allogeneic stem cell transplantation trials in
urope [15,16,31,32], it has yet to be evaluated in the
ontext of nonmyeloablative conditioning. We have
herefore performed experimental studies in a murine
odel of major histocompatibility complex (MHC)–
ncompatible BMT to evaluate a low-dose treosulfan
egimen in combination with T cell–depleting anti-
odies, ﬂudarabine, and thymic irradiation.
ETHODS
nimals
All mice were maintained in microisolator cages
ithin animal facilities that were free of known patho-
ens (Sendai, pneumonia virus of mice, mouse hepa-
itis virus, minute virus of mice, GDVII, respiratory
nteric orphan virus-3, lymphocytic choriomeningitis d
B&MTirus, ECTRO, K, POLY, MAD, EDIM, murine cy-
omegalovirus, HANT, ECUN, MTLV, CARB,
PV NS1, andMycloplasma pulmonis) and treated at 3
onths of age. Female C57BL/6JIco mice (IffaCredo,
’Arbresle, France) were used for assessment of bone
arrow hematopoietic cell content after treatment
ith busulfan or treosulfan, and male C57BL/6J (B6:
-2b) and B10.A (H-2a, Kk, I-Ak, I-Ek, and Dd) mice
Jackson Laboratory, Bar Harbor, ME) were used as
HC-incompatible BMT recipients and donors, re-
pectively.
ssessment of Bone Marrow Hematopoietic Cell
ubset Depletion after Busulfan or Treosulfan
Treosulfan (Ovastat; Medac, Wedel, Germany)
as dissolved in 37°C sterile water at 50 mg/mL and
njected intraperitoneally (IP) in volumes of 0.1
L/10 g body weight (500 mg/kg) at 4, 3, and 2
ays or of 0.2 mL/10 g body weight (1000 mg/kg) at
5, 4, 3, and 2 days before the mice were killed
nd the bone marrow cells were obtained from their
emurs. Busulfan (Busulfex; Orphan Medical,
innetonka, MN) was obtained as a 6 mg/mL busul-
an solution dissolved in N,N-dimethylacetamide
33% wt/wt), and polyethylene glycol 400 (67% wt/
t) and diluted in sterile saline to 1.0 mg/mL and
njected IP in volumes of either 0.1 mL/10 g body
eight (10 mg/kg) at 3 and 2 days or 0.25 mL/10
body weight (25 mg/kg) at5,4,3, and2 days
efore the mice were killed and bone marrow cells
ere harvested.
At 48 hours after drug treatment, bone marrow
ells were harvested from pooled groups of 5 mice and
lated by limiting dilution on conﬂuent layers of the
urine bone marrow stromal cell line FBMD-1 in
6-well plates, as described previously [33]. These
ultures provided growth of hematopoietic precursors
nder the stromal layer, giving the appearance of
obblestone areas in phase-contrast microscopy. The
umber of the different cobblestone area–forming cell
CAFC) subsets per femur was assessed weekly from
ay 10 until day 28 after overlay. This in vitro system
rovided an estimate of the surviving fraction of dif-
erent CAFC day types that correspond to colony-
orming unit–granulocyte-macrophage (CAFC day
), transiently repopulating colony-forming unit–
pleen day 12 (CAFC day 10), and primitive stem cells
ith long-term repopulating ability (CAFC days 30-
0) [33-35].
ecipient Mouse Treatment and BMT
Treosulfan was administered at 500 mg/kg at 4,
3, and 2 days relative to BMT. The maximal
olerated dose for treosulfan has been determined to
e approximately 6000 mg/kg delivered in 3 daily
oses with BMT rescue [36]; animal survival can be
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2aintained without marrow support after single doses
f 3000 mg/kg [5,11,17] or with 3 daily doses of 1500
g/kg [11]. Thus, the total dose of 1500 mg/kg used
n this study should be considered nonmyeloablative.
his also represents a dose of approximately 5 g/m2,
hich is approximately one sixth to one eighth of the
ose currently used in BMT patients (30-42 g/m2)
16,31,32].
Injections of rat immunoglobulin (Ig)G2b anti-
urine CD4 (clone GK1.5) and rat IgG2b anti-mu-
ine CD8 (clone 2.43) were given IP in doses of 2.0
nd 1.4 mg per mouse, respectively, at 5 days with
espect to BMT. Fludarabine phosphate (Fludara;
erlex Laboratories, Richmond, CA) was dissolved in
terile water at a concentration of 30 mg/mL and
njected IP in volumes of 0.1 mL/10 g body weight
300 mg/kg) at 5, 4, 3, 2, and 1 days with
espect to BMT.
At 5 hours before BMT, the mice were anesthe-
ized by IP injection of ketamine hydrochloride 125
g/kg (Bedford Laboratories, Bedford, OH) and xy-
azine 16 mg/mL (Rompun; Bayer Corp., Shawnee
ission, KS) and locally irradiated to the thymus at a
ose of 7 Gy through 11  15-mm radiation portals
Figure 1A) by using a Siemens radiograph machine
perated at 250 kilovolts (peak), per 12 mA (1 mm
u/1 mm Al ﬁlter) and delivered at 1.47 Gy/min.
igure 1. A, Double-exposure simulation radiograph showing the
ositioning of the thymic irradiation (TI) ﬁelds. B, Treatment and
ransplantation protocols using nonmyeloablative BMT condition-
ng with treosulfan (TR), ﬂudarabine (FL), TI, and T cell–depleting
ntibodies (CD4/CD8 ). Either skin grafting or DLI was performed
t 10 weeks after BMT.one marrow cell suspensions in Hanks balanced salt I
38olution were prepared from the long bones of B10.A
ice, and the treosulfan-pretreated B6 recipients were
ntravenously infused via the tail vein with 15  106
ucleated cells. Figure 1B outlines the treatment and
ransplantation protocol.
ssessment of Peripheral Blood Cell Counts
Heparinized blood samples were collected from
ither the tail tip (40 L) or the orbital sinus (100-200
L). For determination of blood cell parameters, 20
L of blood was added to 80 L of phosphate-buff-
red saline (PBS) and assessed for leukocyte and
rythrocyte counts and hematocrit on an EXCELL 10
ET Hematology Analyzer (MWI Inc., Dallas, TX).
or determination of CD3, CD4, and CD8 T-cell
ubset numbers, 20 L of heparinized blood was
ashed with 200 L with ﬂuorescence-activated cell
orter (FACS) buffer (PBS, 0.1% bovine serum albu-
in, and 0.1% sodium azide). A total of 25 L of Fc
locking solution (5 g of 2.4G2 antibody in FACS
uffer) was added and incubated at room temperature
or 5 minutes. A total of 100 L of staining solution (5
g/mL anti–CD3e-PerCP [clone145-2C11], anti–
D4-ﬂuorescein isothiocyanate [FITC; clone RM4-
], or anti–CD8.2-phycoerythrin [clone 53-5.8;
harmingen, San Diego, CA]) was then added to all
amples. A negative control was stained in a similar
anner with Armenian hamster IgG–PerCP, rat
gG2b–FITC, and rat IgG1–phycoerythrin (Pharm-
ngen). Samples were incubated at 4°C for 30 minutes
nd then washed 3 times with 200 L of FACS buffer.
amples were lysed and ﬁxed with FACS lyse solution
Becton Dickinson, Franklin Lakes, NJ) and run on a
ecton Dickinson FACScan.
At selected time intervals, blood was centrifuged at
500 rpm for 6 minutes, and the plasma was collected
nd stored at 80°C for subsequent determination of
at IgG2b levels by enzyme-linked immunosorbent
ssay using mouse anti-rat IgG2b (MARG2b3) and
ouse anti-rat 1 and 3 peroxidase (MARKb and
ARK3, gift of Dominique Latinne, University of
ouvain, Brussels, Belgium) as capture and secondary
ntibodies, respectively.
ssessment of Multilineage Chimerism by Flow
ytometry
All antibodies used for staining were obtained
rom Pharmingen. FcR binding was blocked with
nti-mouse FcR monoclonal antibody (mAb) 2.4G2.
hycoerythrin-conjugated mAbs included anti-CD3e
clone 145-2C11), anti-CD11b (clone M1/70), and
nti-CD45R/B220 (clone RA3-6B2). FITC-conju-
ated anti–H-2Dd (clone 34-2-12) was used to iden-
ify donor-type cells. Phycoerythrin-conjugated non-
peciﬁc Armenian hamster IgG (clone A19-3) and rat
gG2b (clone A95-1) were used as appropriate nega-
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Treosulfan in Nonmyeloablative Conditioning
Bive controls (Pharmingen). Background staining of
ITC-conjugated anti–H-2Dd was determined by
taining a normal host strain (C57BL/6) with this
ntibody.
Allogeneic reconstitution of various lineages in
eripheral blood leukocytes was evaluated by 2-color
ow cytometry (FCM). Red cells were lysed by treat-
ent with ACK lysing buffer (BioWhittaker, Walk-
rsville, MD). Forward-angle and 90° light scatter
roperties were used to distinguish lymphocytes,
ranulocytes, and monocytes in peripheral blood leu-
ocytes, and 2-color FCM was used to distinguish
onor and host cells of particular lineages. Dead cells
ere excluded by gating out low–forward side scatter/
igh–propidium iodide–retaining cells. Acquisition
nd analysis was performed on a Becton Dickinson
ACScan with CellQuest software. Chimerism was
alculated for H2-Dd staining within a particular lin-
age (CD3 or B220 positive of total peripheral blood
eukocytes or CD11b positive gated on monocyte/
ranulocyte proﬁles) after subtraction of a negative
ontrol (blood from untreated C57BL/6 mice) sample.
he limit of detection of donor-type cells was esti-
ated to be approximately 0.5% and 0.8% for the
ymphoid and myeloid lineage, respectively.
kin Grafting
At 10 weeks after BMT, donor-type and third-
arty (SJL; H-2s) full-thickness tail skin grafts were
mplanted under ketamine/xylazine anesthesia accord-
ng to Sharabi and Sachs [37]. Grafts were deﬁned as
ccepted if they were in perfect condition, with tail
airs and scales, and were considered rejected at the
ime of complete sloughing or when they formed a dry
cab. Statistical comparisons of skin rejection rates
mong the different treatment groups were performed
igure 2. Percentage survival of different CAFC subsets remaining i
BU) and treosulfan (TR). Error bars represent 95% conﬁdence limith the Mantel-Haenszel log-rank test. m
B&MTonor Lymphocyte Infusions
Donor splenocytes were prepared from the
pleens by mincing and then passing through an 18-
auge needle. The ﬁltered cell suspension was ad-
usted to 2  107 cells per milliliter in 10 mL of PBS,
nd 5-mL aliquots were overlaid on 5 mL of Lym-
holyte-M (Cedarlane Laboratories Limited, Hornby,
ntario, Canada) and centrifuged at 1450g for 20
inutes at room temperature. Viable lymphocytes
ere harvested from the interface, washed with Hanks
alanced salt solution, and then intravenously infused
nto B6 recipients via the tail vein at doses of 20 106
ells at 10 weeks after BMT.
ESULTS
epletion of Primitive Hematopoietic Cell
ubsets in Recipient Mice after Busulfan or
reosulfan
The percentage survivals for the different CAFC
ay types arising from femoral bone marrow are given
n Figure 2 to show that the low doses of busulfan and
reosulfan had comparable effects, with approximately
0% survival for all hematopoietic cell subsets. Ad-
inistering higher doses of these drugs resulted in far
ore severe CAFC depletion, with less than 1% re-
aining after treatment.
lood Parameters after Low-Dose Treosulfan
reatment and DLI
The nonmyeloablative treosulfan-based prepara-
ive regimens followed by BMT were evaluated for
ematologic toxicity via analysis of blood cell param-
ters. There was no signiﬁcant effect on erythrocyte,
emoglobin, hematocrit, or platelet measurements in
ny of these treatment regimens (data not shown). A
moral bone marrow after treatment with different doses of busulfann the fe
its.oderate decrease in blood leukocyte counts was ob-
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2erved at 1 week after administration of low-dose
reosulfan alone (average of 49% of untreated con-
rols), and a further decrease to an average of approx-
mately 26% of untreated control mice occurred in all
he regimens that contained T cell–depleting mAbs.
reosulfan caused a mild decrease in T-cell subsets by
week (average of 39%, 35%, and 39% among CD3,
D4, and CD8 cells, respectively). A more marked
epression in CD3, CD4, and CD8 T-cell subsets
9.8%, 2.8%, and 11%, respectively) was observed in
he combination treatment groups; this was attributed
o the addition of T cell–depleting antibodies. This
ymphocytopenia persisted over the ﬁrst month for
D4 and for 2 months in the CD8 subsets (data not
hown). Determination of rat IgG2b concentrations of
ollected blood plasma samples showed that adminis-
ration of the high-dose antibodies at 5 days before
MT resulted in high levels in the plasma at 1 week
approximately 50 g/mL) that declined with time
fter transplantation, with a half-life of approximately
days. The recovery in T-cell counts coincided with
he ultimate clearance of these antibodies by 7 weeks
fter BMT. The minimal myelosuppressive properties
f this dose of treosulfan are comparable to those
eported previously for low doses of busulfan or radi-
tion [38,39]. An acute loss in body weight occurred
uring the ﬁrst week in all treated recipient mice
Figure 3). The animals without DLI subsequently
egained their weights and survived in good health
hroughout the experiments (up to 40 weeks) without
ny other apparent health complications.
A late incidence of myelodepression, especially
rythrocytes and related parameters, followed the ad-
inistration of DLI (Figure 4). This effect was most
ronounced in the group preconditioned with T cell–
epleting mAbs, ﬂudarabine, and thymic irradiation
ut without the addition of low-dose treosulfan and
as associated with a signiﬁcant decrease in body
igure 3. Body weight for groups of 5 mice (1 SEM) given comb
hymic irradiation (TI) followed by DLI at 10 weeks after BMT.eight in this group (Figure 3). T
40nduction of Donor-Type Chimerism
FCM analysis of blood samples after BMT showed
ery low or undetectable chimerism in both myeloid
nd lymphoid lineages in recipients pretreated with
ither ﬂudarabine or treosulfan combined with T cell–
epleting mAbs and thymic irradiation. Replacing the
hymic irradiation with ﬂudarabine allowed only tran-
ient chimerism, whereas the full complement of T
ell–depleting mAbs, treosulfan, ﬂudarabine, and thy-
ic irradiation was required to achieve consistent lev-
ls of mixed chimerism, with average levels of approx-
mately 8% (Figure 5). In all cases, the level of
himerism was comparable among myeloid and lym-
hoid lineages to indicate engraftment of pluripotent
tem cells.
Figure 6 shows that although it was difﬁcult to
etect chimerism in the T cell–depleting mAb, ﬂu-
arabine, and thymic irradiation regimen, the infusion
f donor splenocytes at 10 weeks (after complete
learance of T cell–depleting mAbs) subsequently
roduced full donor-type chimerism out to 40 weeks.
he rapid increase in donor-type cells coincided with
yelodepression and weight loss in this group (Fig-
res 3 and 4). Conversion to full chimerism was also
bserved in the group in which the addition of treo-
ulfan to the preparative regimen gave clear mixed
himerism before DLI but had milder effects on sub-
equent blood cell parameters or body weight (Figures
and 4).
cceptance of Donor-Type Skin Grafts
To assess whether hematopoietic chimerism re-
ulted in the development of donor-speciﬁc immuno-
ogic tolerance, transplanted mice were challenged
ith donor-type and third-party skin grafts. Rapid
ejection of donor-type (comparable to third-party)
kin grafts was observed in recipients conditioned with
s of T cell–depleting mAbs, ﬂudarabine (FL), treosulfan (TR), andinationcell–depleting mAbs and thymic irradiation or with
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Bhe treatment combination that did not include thy-
ic irradiation. Addition of treosulfan or ﬂudarabine
o T cell–depleting mAbs and thymic irradiation sig-
iﬁcantly prolonged the time to rejection (P  .005),
hereas the use of all conditioning components en-
bled long-term skin graft survival in all recipients out
o at least 180 days (Figure 7). The prompt rejection
f third-party skin grafts in all the treatment groups
ndicates that graft acceptance was indeed donor spe-
iﬁc and that the animals were immunocompetent
fter the conditioning regimens were applied.
ISCUSSION
This study shows that inclusion of treosulfan in a
onmyeloablative BMT conditioning regimen is
learly associated with increasing engraftment of do-
or stem cells, as seen by long-term maintenance of
ixed chimerism out to 40 weeks after BMT. These
esults are entirely consistent with the potent bone
arrow stem cell–depleting effects of this drug on the
igure 4. Effect of DLI on average blood cell parameters (1 SE
rradiation (TI); anti-CD4/CD8 mAbs, ﬂudarabine (FL), and TI; or
lood cell; PLT, platelets; HCT, hematocrit; RBC, red blood cell.ecipient before transplantation, as shown in the p
B&MTAFC assay of this study and as documented previ-
usly for single doses of treosulfan [17,36]. The de-
letion of all hematopoietic cell subsets, including the
rimitive long-term repopulating CAFCs, is very sim-
lar to that produced by the related compound busul-
an at both nonmyeloablative and myeloablative doses.
survival level of approximately 10% competing stem
ells remaining in the recipient after low-dose treo-
ulfan treatment (Figure 2) thus seems to allow ap-
roximately 8% donor stem cell engraftment in our
MT model (Figure 5), and the peripheral blood cell
ounts indicate that acute myelosuppression is rela-
ively mild (Figure 4). A comparison of a number of
ifferent cytotoxic agents and fractionated radiation
egimens has established that depletion of the long-
erm repopulating CAFC subset in the recipient mar-
ow mirrors the extent of long-term hematopoietic
ngraftment after syngeneic BMT, where levels of
1% host stem cell survival are often necessary before
omplete donor-type chimerism is achieved
17,18,40]. In combination with another T cell–de-
MT recipients pretreated with anti-CD4/CD8 mAbs and thymic
D4/CD8 mAbs, treosulfan (TR), FL, and TI. WBC indicates whiteM) in B
anti-Cleting antibody protocol, van Pel et al. [41] have
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2ecently shown that higher doses of treosulfan (3 
500 and 3  2000 mg/kg) seem to be required for
chieving chimerism from MHC-mismatched BMT
nd that these were associated with donor-speciﬁc
olerance, as shown by skin graft acceptance and as
upported by the interferon- ELISPOT assay. Our
tudy, however, indicates that a more thorough im-
une suppressive regimen consisting of the full com-
lement of T cell–depleting antibodies, ﬂudarabine,
nd thymic irradiation is required to achieve alloge-
eic bone marrow engraftment at lower treosulfan
oses. Indeed, we have recently shown comparable
evels of engraftment of enhanced green ﬂuorescent
rotein (EGFP) transgenic bone marrow after the
ame dose of treosulfan, with minimal immune sup-
ression [39]. Because EGFP is minimally immuno-
enic in C57BL/6 mice, we conclude that the broader
mmune suppressive protocol is necessary for remov-
ng most, if not all, of the genetic resistance imposed
y the MHC-mismatched barrier in this study. Other
tudies in our laboratory have shown similar levels of
llogeneic bone marrow engraftment after the addi-
ion of cyclophosphamide instead of ﬂudarabine to
reosulfan, antibodies, and thymic irradiation. Cyclo-
hosphamide did not seem to be necessary in a low-
igure 5. Myeloid and lymphoid allogeneic donor-type chimerism
mean  SEM for 5 mice per group) after low-dose treosulfan (TR)
n various combinations with anti-CD4/CD8 mAbs, ﬂudarabine
FL), and thymic irradiation (TI). Low or undetectable levels of
himerism were also obtained after anti-CD4/CD8 mAbs, FL, and
I or anti-CD4/CD8 mAbs, TR, and TI in 2 other experiments
data not shown).ose busulfan-based regimen (unpublished data). If it ﬂ
42s accepted that more immune suppression from
gents such as cyclophosphamide or ﬂudarabine is
equired to overcome an MHC-mismatched barrier,
he requirement of depleting recipient stem cells to
ttain long-term chimerism can be achieved compa-
ably by either treosulfan or busulfan.
Very few or undetectable donor-type cells were
bserved after a preparative regimen consisting of
nti–T-cell antibodies, thymic irradiation, and ﬂu-
arabine. The levels of chimerism do seem lower than
hose reported by Pelot et al. [42], who used cyclo-
hosphamide in place of ﬂudarabine. This difference
ay be related to our use of older male mice and a
maller radiation ﬁeld for thymic irradiation, giving
ess of a “bystander” effect from incidental host stem
ell depletion in the surrounding bone marrow [43]. A
uch larger difference lies in comparison with the
linical use of ﬂudarabine-based or cyclophospha-
ide-based conditioning regimens, in which high, and
igure 6. Effect of DLI on myeloid and lymphoid allogeneic
onor-type chimerism (mean SEM for 5 mice per group) in BMT
ecipient mice prepared with anti-CD4/CD8 mAbs and thymic
rradiation (TI) with or without the addition of treosulfan (TR) or
udarabine (FL).
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Bften complete, levels of chimerism have been docu-
ented [24,25,44]. A notable distinction, however, is
he fact that in our animal model, no evidence of
raft-versus-host disease (GVHD) from the initial
ransplantation was observed, whereas a high inci-
ence of GVHD is a recognized problem in patients
25,45]. In our case, the high levels of anti-CD4 and
CD8 mAbs at the time of BMT would have removed
ny alloreactive T cells in the transplanted donor
arrow. Donor T cells were present in the patient
tem cell transplants and likely became activated in a
raft-versus-host type of response that effectively de-
leted host stem cells in patients who received an
therwise non–stem cell–depleting protocol. Such an
ffect has been demonstrated in mice in which high
evels of chimerism were achieved after a cyclophos-
hamide-based regimen in which the T cell–depleting
Abs were omitted from the conditioning regimen
46]. Indeed, such high levels of chimerism were ac-
ompanied by severe GVHD. Furthermore, parallel
tudies with syngeneic BMT resulted in much lower
evels of chimerism, indicating that an allogeneic fac-
or, presumably T cells, contributed to the increased
himerism.
Pelot et al. [42] also described conversion from
ixed to complete chimerism after DLI. It was re-
igure 7. Survival of (A) donor-type (B10.A) and (B) third-party
SJL) skin grafts performed at 10 weeks after BMT. The addition of
ither treosulfan (TR) or ﬂudarabine (FL) to T cell–depleting mAbs
nd thymic irradiation (TI) led to a signiﬁcant delay in the donor-
ype skin rejection rate (P .005), whereas the addition of both TR
nd FL resulted in acceptance of skin grafts out to 180 days.arkable that we found a similar phenomenon in a t
B&MTudarabine-based regimen with extremely low chi-
erism levels (Figure 6). This does indicate that the
ecipients in this group were incapable of rejecting the
onor lymphocytes: the very few preexisting engrafted
onor stem cells were sufﬁcient for tolerance induc-
ion and were capable of complete hematopoietic re-
opulation. Nevertheless, an onset of hematologic de-
ciencies was also observed after DLI in this
reatment group, thus supporting the notion that DLI
rocures complete donor-type chimerism by eradicat-
ng recipient hematopoietic cells. Post-DLI myelo-
uppression and weight loss were more efﬁciently
meliorated in the group that received the treosulfan
onditioning regimen. The addition of treosulfan may
esult in the depletion of host-derived dendritic cells
apable of presenting host antigens to donor T cells,
r the conditioning may result in the emergence of
ither donor- or recipient-derived immunoregulatory
ells. Because the principal distinction of treosulfan
as to facilitate engraftment of more donor stem cells
fter the initial BMT, it seems more likely that some
onor stem cell expansion had occurred at the time of
LI and that these were better able to reconstitute the
ematopoietic system after donor T cell–mediated
estruction of host marrow stem cells. Because donor-
ype skin grafts had prolonged rejection times or were
ermanently accepted, depending on the level of
ixed chimerism in these mice (Figure 7), it would
eem that at least a transient state of immunologic
olerance is required to allow the naive cells in the
LI to exert their effect. Similar ﬁndings have re-
ently emerged from other MHC-mismatched BMT
xperiments in mice with a low-dose busulfan-based
egimen (unpublished data). Of particular interest to
linical application was the absence of GVHD, even
fter DLI. Thus, it seems that a graft-versus-hemato-
oietic effect can be separated from GVHD and that
oth the use of a nonmyeloablative conditioning reg-
men and the timing of DLI are important factors in
chieving this separation. Because conversion from
ixed to full donor hematopoiesis after DLI is com-
only associated with a positive clinical response to
ertain hematologic diseases [47-50], the development
f a protocol that similarly allows separation of a
raft-versus-leukemia effect from GVHD would
learly have important clinical ramiﬁcations.
In conclusion, our results point to an interplay
etween immune suppression and stem cell depletion
fforded by the conditioning regimen, as well as a
raft-versus-hematopoietic effect of donor T cells in
roducing donor stem cell engraftment. In situations
n which GVHD can be circumvented by, for exam-
le, in vivo or ex vivo depletion of donor T cells, then
gents such as treosulfan or busulfan become a more
ssential component of the conditioning regimen.
iven that treosulfan is already reported to have a low
oxicity proﬁle in stem cell transplant patients
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215,16,31,32], the merits of including low-dose treo-
ulfan in nonmyeloablative conditioning regimens in
he clinical setting should be considered.
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